CA
GALT icon

Clearstead Advisors’s Galectin Therapeutics GALT Stock Holding History

Clearstead Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Hold
0
– -$8.32K – 2481
2025
Q4 		– Hold
0
– – – 1911

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Clearstead Advisors's GALT Position: Q1 2026 in Review

Clearstead Advisors held its Galectin Therapeutics (GALT) position steady in Q1 2026 at 6,000 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1485.

Clearstead Advisors first reported a position in GALT in Q2 2023 and has held it in 12 quarters since. The position peaked at $25.4K in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Clearstead Advisors held 6,000 shares of Galectin Therapeutics worth $16.7K as of Q1 2026.
  • Clearstead Advisors left its Galectin Therapeutics share count unchanged in Q1 2026.
  • Galectin Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q1 2026, its #1485 holding.
  • Clearstead Advisors first reported a position in Galectin Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Clearstead Advisors's Galectin Therapeutics position peaked at $25.4K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.